Advancements and Acquisitions Fueled Mid-Cap Biotech R&D Spend in 2014, Says Report

    The combined spend on research and development (R&D) for the peer group of 35 mid-cap biotech companies increased by nearly $2 billion to reach a total of $9.7 billion in 2014, says research and consulting firm GlobalData.   GlobalData's PharmaLeaders: Mid-Cap Biotechnology Benchmark Report states that Regeneron led the way with R&D expenses of $860 million in 2013, with further analysis showing that Regeneron’s R&D expenses grew by 47.9% year-to-year to $1.3 billion in 2014.   Vertex had the second largest R&D outlay among the peer group, spending $855.5 million in 2014, representing a 3% decrease from 2013. R&D in 2014 was also driven by "unexpectedly sharp rises in spending from Jazz and Alnylam".   Click here for more information on the report.